Klin Monbl Augenheilkd 2021; 238(04): 376-377
DOI: 10.1055/a-1425-6458
Der interessante Fall

Failed Descemet Stripping Only (DSO) with Adjuvant Rho-Kinase Inhibitor Therapy in a Fuchsʼ Endothelial Dystrophy Patient: A Case Report

Therapieversagen einer Descemet Stripping only (DSO) mit adjuvanter Rho-Kinase-Inhibitor-Therapie bei einem Patienten mit Fuchs-Endotheldystrophie: ein Fallbericht
1  Eye Clinic, University Hospital of Basel, University of Basel, Switzerland
,
Laura Eggenschwiler
1  Eye Clinic, University Hospital of Basel, University of Basel, Switzerland
,
Peter Meyer
1  Eye Clinic, University Hospital of Basel, University of Basel, Switzerland
,
1  Eye Clinic, University Hospital of Basel, University of Basel, Switzerland
2  Pallas-Kliniken, Bern and Olten, Switzerland
› Institutsangaben

Background

Fuchsʼ endothelial dystrophy is an autosomal dominant inherited corneal disease that is accompanied by a significant decrease in visual acuity [1]. Most corneal transplants worldwide are performed due to this dystrophy [2]. The technique of Descemet stripping only (DSO) – also called descemetorhexis without endothelial keratoplasty (DWEK) – was proposed in 2018 as a new therapeutic option for Fuchsʼ dystrophy [3], [4]. In contrast to lamellar keratoplasty (Descemet Stripping Automated Endothelial Keratoplasty [DSAEK]/Descemet Membrane Endothelial Keratoplasty [DMEK]), DSO does not involve keratoplasty after peeling off the central endothelium. It is expected that the patients remaining surrounding endothelial cells will migrate into the defect independently [5]. Instead of keratoplasty, a cell-based therapy can additionally be performed [5]. In animal experiments, it could be shown that the inhibition of the Rho-kinase pathway led to improved adhesion of corneal endothelial cells and expression of endothelial functional proteins [6], [7]. A recent study demonstrated the superiority of adjuvant therapy with ripasudil, a Rho-kinase inhibitor [8].

We report the case of a failed DSO with adjuvant Rho-kinase inhibitor therapy for Fuchsʼ endothelial corneal dystrophy 1 year after surgery. Visual and histopathological findings are presented.



Publikationsverlauf

Eingereicht: 23. September 2020

Angenommen: 07. März 2021

Publikationsdatum:
30. April 2021 (online)

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany